Recent Research | Page 72 | Aplastic Anemia and MDS International Foundation

Recent Research

Compiled for your convenience are the latest articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology. Articles are obtained from the National Library of Medicine’s MEDLINE database and date back to 2010.

Article Title Original Publication Date Journalsort ascending Bone Marrow Disease
Recent Developments in Drug Therapy for Aplastic Anemia Sep 2014 Ann Pharmacother aplastic anemia
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Sep 2014 Ann Oncol myelodysplastic syndromes (MDS)
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes Oct 2015 Ann Oncol myelodysplastic syndromes (MDS)
Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum Mar 2014 Ann N Y Acad Sci myelodysplastic syndromes (MDS)
Myelodysplastic syndromes in the United States: an update for clinicians Apr 2014 Ann Med. myelodysplastic syndromes (MDS)
A novel marker for screening paroxysmal nocturnal hemoglobinuria using routine complete blood count and cell population data Jan 2015 Ann Lab Med paroxysmal nocturnal hemoglobinuria (PNH)
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Apr 2012 Ann Hematol. aplastic anemia
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide May 2014 Ann Hematol myelodysplastic syndromes (MDS)
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II Nov 2016 Ann Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol Aug 2016 Ann Hematol myelodysplastic syndromes (MDS)